VRCA Verrica Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1660334 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY370.2%
TTM net income YoY76.6%
TTM EPS YoY88.6%
Revenue 3-yr CAGR57.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-34.2%
Net margin-50.3%
FCF margin—
EBITDA margin-33.9%
Returns
ROE-240.4%
ROA-35.3%
ROIC (approx.)—
Asset turnover0.70x
Leverage & solvency
Liabilities / assets47.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-1.57x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $35.58M | $7.57M | $5.12M | $9.03M | $12.00M |
| Cost of revenue | — | $2.60M | $500,000 | — | — |
| Gross profit | — | $4.97M | $4.62M | — | — |
| R&D expense | $8.86M | $11.84M | $20.30M | $12.20M | $15.93M |
| SG&A expense | $35.22M | $58.82M | $47.30M | $17.41M | $26.98M |
| Operating income | -$12.19M | -$65.92M | -$65.76M | -$21.30M | -$30.91M |
| Interest expense | $7.74M | $9.41M | $3.96M | $2.17M | $4.29M |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | -$35.08M |
| EBITDA | -$12.05M | -$65.58M | -$65.23M | -$20.84M | -$30.66M |
| EPS (basic) | -1.68 | -14.78 | -1.48 | -0.72 | -1.30 |
| EPS (diluted) | -1.68 | -14.78 | -1.48 | -0.72 | -1.30 |
| Weighted avg. shares (diluted) | 10.65M | 5.18M | 45.34M | 34.16M | 27.04M |
| Balance sheet | |||||
| Cash & equivalents | $30.15M | $46.33M | $69.55M | $34.27M | $15.75M |
| Short-term investments | — | — | — | $0 | $0 |
| Receivables | $5.26M | $48,000 | $4.25M | $0 | — |
| Inventory | $2.24M | $2.46M | $1.02M | $0 | — |
| Current assets | $42.54M | $51.18M | $77.53M | $39.12M | $74.33M |
| PP&E, net | $209,000 | $589,000 | $1.05M | $3.89M | $3.89M |
| Total assets | $47.13M | $54.13M | $81.60M | $44.72M | $80.12M |
| Current liabilities | $16.44M | $29.01M | $17.02M | $3.46M | $46.05M |
| Short-term debt | $0 | $12.94M | $0 | $0 | $41.69M |
| Long-term debt | $0 | $30.98M | $42.87M | $0 | — |
| Total debt | $0 | $43.92M | $42.87M | $0 | — |
| Total liabilities | $22.39M | $63.99M | $61.83M | $4.69M | $47.52M |
| Shareholders' equity | $24.74M | -$9.86M | $19.76M | $40.03M | $32.60M |
| Net debt | -$30.15M | -$2.41M | -$26.67M | -$34.27M | — |
| Shares outstanding | 17.18M | 9.18M | 42.41M | 41.09M | 27.52M |
| Cash flow statement | |||||
| Operating cash flow | -$17.63M | -$60.93M | -$38.58M | -$18.65M | -$27.58M |
| Capital expenditure | $0 | $27,000 | $362,000 | $302,000 | $883,000 |
| Free cash flow | -$17.63M | -$60.95M | -$38.94M | -$18.95M | -$28.46M |
| Investing cash flow | $0 | -$19,000 | -$362,000 | $54.04M | -$998,000 |
| Financing cash flow | $1.45M | $37.73M | $74.21M | -$16.87M | $33.65M |
| Depreciation & amortization | $133,000 | $342,000 | $530,000 | $454,000 | $244,000 |
| Stock-based compensation | $3.32M | $7.16M | $14.38M | $4.99M | $6.05M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.